- Home
- THCH vs IMMX Comparison
THCH vs IMMX Comparison
Compare THCH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- IMMX
- Stock Information
- Founded
- THCH 2018
- IMMX 2014
- Country
- THCH China
- IMMX United States
- Employees
- THCH N/A
- IMMX N/A
- Industry
- THCH Blank Checks
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- THCH Finance
- IMMX Health Care
- Exchange
- THCH Nasdaq
- IMMX Nasdaq
- Market Cap
- THCH 84.2M
- IMMX 82.6M
- IPO Year
- THCH N/A
- IMMX 2021
- Fundamental
- Price
- THCH $2.49
- IMMX $3.05
- Analyst Decision
- THCH
- IMMX Strong Buy
- Analyst Count
- THCH 0
- IMMX 1
- Target Price
- THCH N/A
- IMMX $8.00
- AVG Volume (30 Days)
- THCH 12.0K
- IMMX 453.7K
- Earning Date
- THCH 11-11-2025
- IMMX 11-11-2025
- Dividend Yield
- THCH N/A
- IMMX N/A
- EPS Growth
- THCH N/A
- IMMX N/A
- EPS
- THCH N/A
- IMMX N/A
- Revenue
- THCH $187,316,342.00
- IMMX N/A
- Revenue This Year
- THCH N/A
- IMMX N/A
- Revenue Next Year
- THCH N/A
- IMMX N/A
- P/E Ratio
- THCH N/A
- IMMX N/A
- Revenue Growth
- THCH N/A
- IMMX N/A
- 52 Week Low
- THCH $1.95
- IMMX $1.34
- 52 Week High
- THCH $5.15
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- THCH 40.41
- IMMX 77.89
- Support Level
- THCH $2.39
- IMMX $2.31
- Resistance Level
- THCH $2.74
- IMMX $2.82
- Average True Range (ATR)
- THCH 0.11
- IMMX 0.25
- MACD
- THCH -0.01
- IMMX 0.08
- Stochastic Oscillator
- THCH 28.97
- IMMX 95.41
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.